Pristimerin Protects Against Doxorubicin-Induced Cardiomyopathy and Fibrosis | ||||
| Cardiovascular Research Prove Journal | ||||
| Volume 3, Issue 1, June 2019 PDF (34.72 K) | ||||
| Document Type: Abstracts | ||||
| DOI: 10.21608/cvrepj.2019.351824 | ||||
 View on SCiNiTO | ||||
| Abstract | ||||
| Pristimerin (Pris) is triterpenoid compound with many biological effects. Until now, nothing is known about its effect on doxorubicin (DOX)-induced cardiotoxicity. Hence, this study investigated the impact of Pris on DOX-induced cardiotoxic effects. | ||||
|
Statistics Article View: 66 PDF Download: 27 |
||||
